ASCO 2019 | Radium-223 label change

Bertrand Tombal

Bertrand Tombal, MD, PhD, of the Cliniques Universitaires Saint-Luc, Brussels, Belgium give his opinion on the European Medicines Agency’s (EMA) change to the label for Radium-223 for the treatment of metastatic castration-resistant prostate cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  
Similar topics
Related videos
2:33
irAEs with single-agent PD-1 vs PD-L1 inhibitors
Petros Grivas
3:48
Urothelial carcinoma: maintenance therapies
Petros Grivas
4:20
IMvigor130 data: atezolizumab alone or with chemo upfront for bladder cancer
Thomas Powles
3:19
PD1 & PDL1 inhibitors for mUC, where are we?
Petros Grivas
1:53
Updated FIERCE-22 data: vofatamab with pembrolizumab for mUC
Arlene Siefker-Radtke
Genitourinary Cancer, Prostate Cancer
Abiraterone, Radium-223
ASCO 2019
Interview
2nd June 2019
More from Bertrand Tombal
PROSPER: Enzalutamide vs. placebo for nmCRPC
Survivorship in high risk localized prostate cancer
A patient-centered approach to cancer treatment decision-making
vjoncology logo VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals